Introduction
============

With the increasing numbers and types of resistant organisms, there is an increasing need for antibiotics to treat infections caused by them. Daptomycin is a cyclic lipopeptide with a broad spectrum of activity against gram-positive organisms, both aerobic and anaerobic. This includes resistant strains as well such as methicillin-resistant *Staphylococcus aureus* (MRSA), glycopepetide-intermediate *Staphylococcus aureus* (GISA), vancomycin-resistant enterococci (VRE), coagulase-negative staphylococci (CoNS), and penicillin-resistant *Streptococcus pneumoniae* (PRSP).

Daptomycin was discovered in the early 1980s, at Eli Lilly and Company ([@b38]). Daptomycin was initially developed in the late 1980s and early 1990s but was ultimately shelved due to concerns regarding adverse effects, in particular drug-induced myopathy. Cubist Pharmaceuticals Inc. licensed worldwide rights from Eli Lilly and Company in 1997 ([@b38]).

Basics/mechanism of action
==========================

Daptomycin is derived as a fermentation product from *Streptomyces roseospours*. The unique structure of daptomycin consists of a 13-member amino acid cyclic lipopeptide with a decanoyl side-chain ([@b35]) ([Figure 1](#fig1){ref-type="fig"}). Daptomycin molecular weight is 1620.67 ([@b7]). This is a rather large molecule which may influence its distribution into tissues.

![Structure of daptomycin. Copyright © 2005. Reproduced with permission from Steenbergen JN, Alder J, Thorne GM, et al. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. *J Antimicrob Chemother*, 55:283--8.](tcrm0202-169-f1){#fig1}

The exact details of daptomycin\'s mechanism of action are not completely understood. It is believed to have a unique mechanism of action that involves calcium-dependent insertion of the lipophilic daptomycin tail into the bacterial cell membrane, causing rapid depolarization and potassium ion efflux ([@b35]) ([Figure 2](#fig2){ref-type="fig"}). It has been observed that daptomycin causes a calcium-dependent dissipation of the membrane potential (Δ psi) in *Staphylococcus aureus* without noticeably affecting the chemical gradient (Δ pH) across the membrane ([@b3]). This unique mechanism of action makes daptomycin rapidly bactericidal.

![Proposed mechanism of action of daptomycin. Hypothetical steps: step 1, daptomycin binds to the cytoplasmic membrane in a calcium-dependent manner; step 2, daptomycin oligomerizes, disrupting the membrane; step 3, the release of intracellular ions and rapid cell death. Copyright © 2005. Reproduced with permission from Steenbergen JN, Alder J, Thorne GM, et al. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. *J Antimicrob Chemother*, 55:283--8.](tcrm0202-169-f2){#fig2}

Pharmacokinetics
================

Daptomycin exhibits linear pharmacokinetics across a wide range of doses with once daily dosing up to 6 mg/kg ([Figure 3](#fig3){ref-type="fig"}) ([@b42]; [@b8]). Daptomycin doses of 8 mg/kg exhibit a slight nonlinearity ([@b8]).

![Linearity of dose versus area under the curve (AUC). Copyright © 1992. Reproduced with permission from [@b42]. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. *Antimicrob Agents Chemother*, 36:318--25.](tcrm0202-169-f3){#fig3}

Approximately 92% of daptomycin is protein-bound ([@b42]). Excretion of the drug occurs primarily via the kidney with approximately 80% of the total dose, of which two-thirds is intact drug, recovered in the urine ([@b38]). Due to daptomycin\'s predominant renal clearance, it requires dose adjustments in those with impaired renal function. Daptomycin clearance in females is estimated to be approximately 80% that of males with similar renal function, although this has otherwise not been shown to be statistically or clinically significant ([@b9]).

The observed t~½~ is relatively long (∼9 hours) ([@b8]). The long t~½~ allows for once daily dosing in patients with normal renal function. Daptomycin t~½~ is increased by 2.3-fold in patients with creatnine clearance (CLcr) \<40 mL/min and 3.5-fold in patients on dialysis ([@b9]).

Daptomycin remains in the plasma and interstitial fluid and therefore has a small volume of distribution ([@b8], [@b9]).

The maximum serum concentration after escalating single daily doses of daptomycin ranged from approximately 55, 85 to 95 μg/mL, and 115 to 130 μg/mL with doses of 4, 6, and 8 mg/kg, respectively ([@b8]). The area under the curve following doses of 4, 6, and 8 mg/kg/day revealed similar linearity to the C~max~ pharmacokinetic data above ([@b8], [@b9]).

Daptomycin has been shown to exhibit a post-antibiotic effect (PAE) on *Staphylococcus aureus* and *Streptococcus pneumoniae* ([@b27]; [@b32]). The PAE combined with the long t~½~ of daptomycin allows for once daily dosing in patients with normal renal function.

Daptomycin should not be used to treat pneumonia. This is due to the fact that daptomycin is inhibited by surfactant ([@b34]).

Spectrum of activity
--------------------

As mentioned before, daptomycin has a broad spectrum of activity against gram-positive organisms, both aerobic and anaerobic. This includes resistant strains as well such as MRSA, GISA, VRE, CoNS, and PRSP. Calcium concentration of the media is an important factor in interpreting susceptibility testing ([@b14]). The manufacturer recommends susceptibility testing with broth microdilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L ([@b7]). Below are the minimum inhibitory concentration of anti-infective needed to inhibit the growth of 90% of strains (MIC~90~s) of a variety of gram-positive organisms from various in vitro studies:

-   *Staphylococcus aureus\** MIC 0.5 mg/L ([@b36]) (\*without a breakdown into MSSA and MRSA).

-   MSSA MIC 0.25 to 0.5 mg/L ([@b41]; [@b15]; [@b29]).

-   MRSA MIC 0.5 to 1.0 mg/L ([@b41]; [@b15]; [@b29]).

-   GISA MIC 0.125--0.5 mg/L ([@b1], [@b2]). No differences were seen for susceptibility of *vanA*, *vanB1*, and *vanD* strains ([@b18]).

-   VRSA: Daptomycin was found to be bactericidal against a VRSA (strain HMC3) isolated in Pennsylvania, US that was resistant to vancomycin through the presence of the *vanA* resistance gene; it also contained *mecA*, *erm*(A), *erm*(B), *tet*(K) and *aac*(6\')-*aph*(2′′), conferring resistance to licensed ß-lactams, macrolides, tetracycline and aminoglycosides ([@b5]).

-   CoNS 0.5 mg/L ([@b41]; [@b15]; [@b31]; [@b36]).

-   *Enterococcus fecalis\*\** MIC 1 to 2 mg/L ([@b41]; [@b29]; [@b36]) (\*\*Enterococci were defined as vancomycin susceptible and those not further defined. If known to be VRE then stated as such).

-   Vancomycin-resistant *Enterococcus fecalis* MIC 1 to 4 mg/L ([@b29]; [@b31]).

-   *Enterococcus faecium* MIC 2 to 4 mg/L ([@b41]; [@b29]; [@b36]).

-   Vancomycin-resistant *Enterococcus faecium* MIC 2 to 4 mg/L ([@b29]; [@b31]).

-   *Streptococcus pneumoniae* MIC 0.25 mg/L ([@b41]; [@b36]).

-   PRSP MIC 0.25 mg/L ([@b31]).

Susceptibility breakpoints for as set forth by the Food and Drug Administration (FDA), which are the same as those from the National Committee for Clinical Laboratory Standards, are as follows ([@b7]; [@b37]):

-   *Staphylococcus aureus* (MSSA and MRSA) \<1 mg/L

-   *Streptococcus spp.* (*S. pyogenes, S. agalactiae*, and *S.dysgalactiae* subsp. equisimilis) ≤1 mg/L

-   *Enterococcus fecalis* (vancomycin-susceptible only) \<4 mg/L

Resistance
----------

There appears to be a low rate of spontaneous resistance to daptomycin with limited increases in MIC and relative ease of treatment of resistant isolates ([@b33]).

Population analysis of three *Staphylococcus aureus* isolates for which the daptomycin MICs were 8 mg/mL showed a pattern of homogeneous resistance ([@b18]).

There have been multiple case reports of gram-positive organisms with daptomycin resistance, these include MRSA ([@b22]), *Enterococcus faecium* ([@b30]; [@b21]), and *Enterococcus fecalis* ([@b24]).

Adverse drug reactions
======================

Early in clinical trials daptomycin was found to have skeletal muscle effects that included myopathy with muscle weakness and elevated serum creatine phosphokinase (CPK). Further testing using a dog model revealed that this was more of a problem with fractioned dosing that could be overcome by changing the dosing schedule to once daily from every twelve hours ([@b26]).

Daptomycin is generally well tolerated ([@b8]; [@b4]). A large randomized trial evaluating the safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections (cSSSI) involving 1092 patients revealed the frequency, distribution, and severity of adverse events to be similar for daptomycin and standard therapy ([@b4]) ([Table 1](#tbl1){ref-type="table"}).

###### 

Adverse events that occurred in \<2% of patients in either treatment group ([@b4])

                                         n (%) of patients   
  -------------------------------------- ------------------- ----------
  Constipation                           33 (6.2)            38 (6.8)
  Nausea                                 31 (5.8)            53 (9.5)
  Injection site reaction                31 (5.8)            43 (7.7)
  Headache                               29 (5.4)            30 (5.4)
  Diarrhea                               28 (5.2)            24 (4.3)
  Insomnia                               24 (4.5)            30 (5.4)
  Rash                                   23 (4.3)            21 (3.8)
  Vomiting                               17 (3.2)            21 (3.8)
  Abnormal liver function test results   16 (3.0)            9 (1.6)
  Pruritus                               15 (2.8)            21 (3.8)
  Elevated serum CPK level               15 (2.8)            10 (1.8)
  Fungal infection                       14 (2.6)            18 (3.2)
  Hypotension                            13 (2.4)            8 (1.4)
  Urinary tract infection                13 (2.4)            3 (0.5)
  Renal failure                          12 (2.2)            15 (2.7)
  Dizziness                              12 (2.2)            11 (2.0)
  Anemia                                 11 (2.1)            13 (2.3)
  Dyspnea                                11 (2.1)            9 (1.6)
  Fever                                  10 (1.9)            14 (2.5)
  Limb pain                              8 (1.5)             11 (2.0)
  Hypertension                           6 (1.1)             11 (2.0)
  Dyspepsia                              5 (0.9)             14 (2.5)
  Arthralgia                             5 (0.9)             12 (2.2)

**Note**: ^a^Cloxacillin, flucloxacillin, nafcillin, oxacillin, or vancomycin.

**Abbreviations**: CPK, creatine phosphokinase.

Copyright © 2004. Reproduced with permission from Arbeit RD, Maki D, Tally FP, et al 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis, 38:1673--81.

There was a case report of significant myopathy with daptomycin without pronounced CPK elevation (CPK \<500 U/L) at a dose of 6 mg/kg intravenously per day ([@b40]). There has also been a case report of myopathy and possible hepatotoxicity in a patient with underlying chronic liver disease, but the elevations in the transaminases were mild (aspartase aminotransferase 239 U/L and alanine aminotransferase 48 U/L) ([@b12]). It is recommended by the manufacturer that in patients with unexplained signs and symptoms of myopathy in conjunction with CPK elevation \>1000 U/L, or in patients without reported symptoms who have marked elevation in CPK (≥10x ULN), daptomycin should be discontinued ([@b7]).

Drug--drug interactions
=======================

Daptomycin is without any known significant drug--drug interactions. Nonetheless, the manufacturer recommends giving consideration to temporarily discontinuing use of HMG CoA reductase inhibitors while patients receive daptomycin ([@b7]). This is recommended due to the potential confusion that may arise if a patient on an HMG CoA reductase inhibitor were to experience myopathy or an increase in CPK level.

Clinical uses
=============

Daptomycin is currently only approved for the treatment of cSSSI caused by susceptible *Staphylococcus aureus* (MSSA and MRSA), *Streptococcus spp.* (*S. pyogenes, S. agalactiae*, and *S. dysgalactiae* subsp. equisimilis), and *Enterococcus fecalis* (vancomycin-susceptible only) ([@b7]; [@b4]). This includes diabetic foot ulcers ([@b4]; [@b20]).

Daptomycin has proven to be effect in multiple experimental endocarditis models. In a retrospective analysis of 49 patients with endocarditis due to gram-positive organisms, daptomycin dosed at \>6 mg/kg intravenously every 24 hours showed high cure rates ([@b19]).

There have also been case reports of successful treatment of prosthetic valve endocarditis in humans ([@b23]). Daptomycin trials in human endocarditis are currently in progress.

In an experimental animal (rabbit) model of meningitis due to penicillin- and quinolone-resistant *Streptococcus pneumoniae,* daptomycin looked promising when compared with the combination of ceftriaxone and vancomycin ([@b6]).

In an experimental model of *Staphylococcus aureus* ventriculitis in hydrocephalic rabbits, daptomycin was detectable in the periventricular white matter but in amounts too small to quantitate. Daptomycin killed more *Staphylococcus aureus* more rapidly than vancomycin in this model ([@b16]).

Daptomycin also appears to be a promising for the treatment of peritoneal dialysis-associated peritonitis due to staphylococci and streptococci in an in vitro peritoneal dialysate model ([@b17]).

A trend toward equivalent efficacy between intravenous daptomycin and intravenous ciprofloxacin was observed in the treatment of gram-positive urinary tract infections in which *Enterococcus faecalis* and *Staphylococcus aureus* were the most common gram-positive pathogens ([@b25]). Based on the previously mentioned susceptibilities and the fact that daptomycin is predominately renally excreted, one would predict that daptomycin should be effective in the treatment of urinary tract infections due to such pathogens, but this warrants further studies.

Daptomycin was at least equivalent to vancomycin against chronic foreign body infections due to *Staphylococcus aureus*, though vancomycin has poor activity in these infections. In a prospective study of daptomycin in the treatment of prosthetic joint infections, 5 of 7 patients with MRSA infections experienced treatment failures, so the efficacy of daptomycin in the treatment of prosthetic joint infections is uncertain ([@b28]).

Daptomycin should not be used to treat pneumonia. This is due to the fact that daptomycin is inhibited by surfactant ([@b34]).

Dose
====

The dose of daptomycin is 4 mg/kg intravenously every 24 hours for patients with normal renal function ([@b7]; [@b4]). For patients with a creatinine clearance of less than 30 mg/min, including those patients on hemodialysis, continuous ambulatory peritoneal dialysis, or continuous renal replacement therapy (CRRT) which includes continuous arteriovenous hemofiltration (CAVH), continuous venovenous hemofiltration (CVVH), continuous arteriovenous hemodialysis (CAVHD), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodialfiltration (CVVHDF), the dose is 4 mg/kg intravenously every 48 hours ([@b7]; [@b4]; [@b39]). Patients with moderate hepatic impairment receiving daptomycin do not require an adjustment in daptomycin dose or dose regimen ([@b10]). No adjustment in daptomycin dose or dose regimen should be required based solely on obesity ([@b11]). An international, multicenter, randomized open label trial using the off-label dose of daptomycin at 6 mg/kg every 24 hours showed that this dose was similar in efficacy to standard therapy for Staphylococcus aureus bacteremia and endocarditis ([@b13]).

Conclusion
==========

Daptomycin is a cyclic lipopeptide antibiotic with excellent activity against gram-positive organisms. Although there have been case reports of daptomycin-resistant gram-positive organisms, it has a unique mechanism of action that renders it bactericidal. Daptomycin is given once a day and is renally cleared, requiring dose adjustment in patients with impaired renal function. Daptomycin is generally well tolerated, though myopathy has been reported. Daptomycin is currently approved for use in skin and soft-tissue infections and shows promise in experimental models of endocarditis, meningitis, ventriculitis, and peritonitis.
